Ireland· IE-PA-PA0540/082/001
Triapin 2.5mg/2.5mg prolonged release tablet
A ramipril and felodipine product containing felodipine + ramipril, registered in Ireland by Sanofi-Aventis Ireland Limited T/A SANOFI. The same ATC class is registered in 6 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Ramipril and felodipine is registered in 6 of 19 countries.
Countries holding a registration under ATC C09BB05 (ramipril and felodipine), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 4 of them publish a price we can compare per daily dose
Ramipril and felodipine · ATC C09BB05
6 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Ireland
- Polandprice
- United Kingdom
The record
At a glance
HPRA (Ireland)- Active substance
- Felodipine + Ramipril
- Manufacturer
- Sanofi-Aventis Ireland Limited T/A SANOFI
- Country
- Ireland (IE)
- ATC code
- C09BB05
- ATC class
- Ramipril and felodipine
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA0540/082/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
40 interactions on record for ramipril and felodipine.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ramipril and felodipine · interactions on record
40 records
40 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Ramipril and felodipine in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomTriapin 2.5mg/2.5mg modified-release tabletsLexon (UK) Ltd
- CzechiaTRIASYNSanofi s.r.o., Praha
- FinlandUnimaxAstraZeneca Oy
- PolandDelmuno 2,5Sanofi-Aventis Deutschland GmbH
- SwedenTazko 5 mg/5 mg DepottablettSanofi AB
- SpainTRIAPIN 5 mg/5 mg COMPRIMIDOS DE LIBERACION PROLONGADASanofi Aventis S.A.
- GermanyDelmunoSanofi-Aventis Deutschland Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 12 EEA countries. Names it is sold under:
- Belgium · Tazko
- Cyprus · Triacor
- Czechia · Triasyn
- Germany · Delmuno
- Spain · Triapin
- Greece · Triacor
- Croatia · Triapin
- Hungary · Triasyn
- Italy · Triapin
- Luxembourg · Tazko
- Poland · Delmuno
- Portugal · Triapin, Triapin Mite
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e2debfcd-1c5b-4818-9de4-7666af9d7c9a GET /v1/drugs/e2debfcd-1c5b-4818-9de4-7666af9d7c9a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Prolonged-release tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"C09BB",
"C09BB05"
],
"strength": null,
"pa_number": "PA0540/082/001",
"substances": [
"Felodipine",
"Ramipril"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "13/07/1998",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about ramipril and felodipine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.